Panagora Asset Management’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Panagora Asset Management’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-2,480	Closed	-$11K	–	2569
2016 Q2	$11K	Hold	2,480	–	–	﹤0.01%	2225
2016 Q1	$14K	Sell	2,480 -1,689	-41%	-$21.9K	﹤0.01%	2184
2015 Q4	$72K	Buy	4,169 +2,393	+135%	+$57.1K	﹤0.01%	1884
2015 Q3	$37K	Sell	1,776 -930	-34%	-$31.9K	﹤0.01%	2061
2015 Q2	$134K	Sell	2,706 -384	-12%	-$23K	﹤0.01%	1857
2015 Q1	$242K	Buy	+3,090	New	+$192K	﹤0.01%	1600

Other funds holding OREX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Panagora Asset Management's OREX Position: Q3 2016 in Review

Panagora Asset Management sold out of Orexigen Therapeutics, Inc. (OREX) in Q3 2016, closing a stake of 2,480 shares — an estimated $11K sold.

Panagora Asset Management first reported a position in OREX in Q1 2015 and held it in 6 quarters. The position peaked at $242K in Q1 2015. 55 funds tracked by Wall St. Rank hold OREX as of Q3 2016.

Panagora Asset Management reported no remaining Orexigen Therapeutics, Inc. position as of Q3 2016 after selling out during the quarter.
Panagora Asset Management sold 2,480 Orexigen Therapeutics, Inc. shares in Q3 2016, an estimated $11K.
Panagora Asset Management first reported a position in Orexigen Therapeutics, Inc. in Q1 2015 and held it in 6 quarters.
Panagora Asset Management's Orexigen Therapeutics, Inc. position peaked at $242K in Q1 2015.
55 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q3 2016.

Based on Panagora Asset Management's 13F filing for Q3 2016, filed 14 Nov 2016.